February 27, 2018 / 1:14 PM / 3 months ago

BRIEF-Tetraphase Pharmaceuticals Says FDA Accepted NDA Filing For cIAI Treatment Eravacycline

Feb 27 (Reuters) - Tetraphase Pharmaceuticals Inc:

* TETRAPHASE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR FILING OF ITS NDA SUBMISSION FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

* TETRAPHASE PHARMACEUTICALS INC - PDUFA GOAL DATE FOR COMPLETION OF FDA’S REVIEW OF ERAVACYCLINE NDA IS SET FOR AUGUST 28, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below